{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Analyses will be descriptively summarized.","groups":[{"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nTrametinib: Given PO\n\nUprosertib: Given PO","id":"OG000","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"populationDescription":"Data for this measure was not analyzed","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Chromosomal Abnormalities as Determined by FISH","type":"OTHER_PRE_SPECIFIED"}